Skip to content
Search

Latest Stories

NHS chief thanks staff for ‘extraordinary team effort’ in face of Omicron

The new NHS chief executive Amanda Pritchard acknowledged and thanked health service staff and volunteers for their “extraordinary team effort” while the country fights Omicron.

Pritchard, who took up the post in July, praised the efforts of doctors, nurses, therapists, porters and other staff who have worked hard to recover services impacted by the Covid-19 pandemic.


In her first Christmas message as the NHS chief, she praised all those involved in the NHS Covid vaccination programme which delivered more than 7 million jabs, including boosters, in the last 10 days alone.

She said: “We’ve had another extraordinary 12 months.

“From January when hospitals admitted 100,000 patients with Covid in a single month, while also delivering the world-class NHS covid vaccination programme; to receiving the George Cross during the summer, marked by a service at St Paul’s, pulling out all the stops to make progress on recovering backlogs of care; and now facing the uncertainty of Omicron and winter pressures.

“The pandemic is the greatest challenge in the NHS’s history and the defining challenge of our professional lives”.

She added that health service staff have worked “at record speed to turbo-charge the NHS Covid-19 booster programme and protect communities against the Omicron variant.”

Pritchard went on to praise the public for their response in recent months to the new variant, as more than 18 million people have booked in for a booster and more than 25 million people have had their top-up, since September.

Besides the vaccination programme, staff have continued to provide care to patients, answering the highest number of 999 calls for any November.

This year the NHS has also rolled out new, revolutionary drugs, and implemented innovative treatments, including for Spinal Muscular Atrophy, type one diabetes, sickle cell disease, stroke, lung cancer, cystic fibrosis and hepatitis C.

Pritchard finished her annual address to staff and patients, by thanking NHS staff who have worked relentlessly this year, and last year, and will continue to do so throughout Christmas and into next year.

Vaccination will continue on Christmas Day and Boxing Day at sites across to protect as many people as possible in the face of the threat from Omicron.

She said: “My very best wishes to you, and to your families and friends, who I know provide such vital support throughout the year.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less